From 2024 to 2031, the worldwide asthma treatment market is expected to develop at a CAGR of 4.8%. USD 18.2 billion is the estimated market size in 2022; by 2031 it is predicted to rise to USD 26.1 billion. With advanced healthcare infrastructure and high asthma incidence, North America now rules the industry.
Driven by increasing global asthma prevalence, escalating air pollution, rising healthcare spending, and developments in drug delivery technologies, the market for asthma treatments is consistently expanding. Strong pipeline of new treatments, including biologics and combination medicines, targeted at giving patients with severe or uncontrolled asthma more individualized and effective treatment options defines the market.
Market Trend: Shift in market trend toward biologics and tailored treatments for severe asthma
Particularly for those with severe or uncontrolled asthma, the scene of asthma treatment is changing significantly toward biologics and tailored treatments. For individuals who do not react sufficiently to traditional treatments, these cutting-edge therapeutics—monoclonal antibodies targeting particular inflammatory pathways—offer more individualized and successful choices. Promising findings in lowering exacerbations and enhancing lung function in particular patient categories have come from biologics like omalizumab, mepolizumab, and dupilumab. Growing knowledge of the variety of asthma and the necessity of precision treatment techniques motivate this development. Particularly in developed areas with more healthcare expenditure, more biologics predicted to join the market and achieve wider acceptance among healthcare professionals should take a bigger percentage of the asthma treatment market.
Market Driver: Growing environmental contamination and a rising asthma prevalence
A major factor influencing the asthma treatment market is the rising global prevalence of asthma together with rising environmental pollution. Over 300 million individuals worldwide suffer from asthma; by 2025, that figure is anticipated to climb to 400 million. Urbanization, industrialization, and climate change among other things help to impair air quality, which can aggravate asthma symptoms and raise the demand for sensible therapies. Further driving market expansion are changes in lifestyle, genetic elements, and rising awareness of asthma diagnosis. The growing disease load not only raises the need for current treatments but also stimulates research and development of creative ideas. Asthma management initiatives being undertaken by governments and healthcare institutions also help to increase the market for asthma medications.
Market Restraint: Control on the Market Patent expirations and increasing general competitiveness
One main challenge to the asthma industry is the expiration of patents for significant asthma medications and the concomitant increase in generic competition. As patents on long-acting beta-agonists and popular inhaled corticosteroids expire, generic copies of these pharmaceuticals find their way onto the market and reduce market share for branded drugs, hence driving price discounts. This inclination might influence not just the sources of income for large pharmaceutical companies but also their capability for investing in innovative drug research. Though it lowers costs for patients, it may discourage field innovation. Companies are responding by focusing on developing novel combination medicines, looking at alternate delivery systems, and supporting biologics with longer patent protection. Still, the pressure from generic competition remains a major barrier to market development and profitability for established companies in the arena of asthma therapy.
Medications Classed as Long-Term Control Dominate
Still mostly dominating the asthma treatment market are long-term control drugs, especially inhaled corticosteroids. By lowering airway inflammation and hence preventing symptoms, these drugs are absolutely vital for controlling ongoing asthma.
For many patients, long-term control drugs—including inhaled corticosteroids, long-acting beta-agonists, and leukotriene modifiers—form the cornerstone of asthma care. Their first-line treatment status for chronic asthma has been confirmed by their efficiency in lowering inflammation, preventing aggravations, and enhancing general lung capacity. Guidelines suggesting regular usage of these drugs for best asthma control support the segment's predominance even more.
Leading the market with advanced healthcare infrastructure and great prevalence is North America.
Driven by high prevalence rates and a strong healthcare system supporting new therapies, North America rules the worldwide asthma treatment market. Particularly the United States, North America has the biggest proportion of the asthma treatment market. Strong reimbursement policies, advanced healthcare infrastructure, and a large prevalence of asthma (affecting approximately 8% of the U.S. population) help to explain this predominance. The area leads in implementing creative treatments such smart inhalers and biologics. Market expansion also comes from the presence of big pharmaceutical companies, continuous clinical research, and large healthcare expenditure. Demand for different treatment choices is further driven by the focus on asthma management programs and patient education, therefore confirming North America's top ranking in the world asthma treatment market.
Strong competition among both existing pharmaceutical corporations and newly founded biotech startups defines the market for asthma treatment. Important players concentrate on creating creative medicines to meet unmet requirements in severe asthma treatment, especially in the biologics section. As businesses try to increase their product lines and worldwide presence, strategic alliances, mergers, and acquisitions are rather typical. With a great pipeline of new medications and delivery technologies, the market also sees notable investment in research and development. As patents expire, generic producers are joining the market more and more, hence raising price competition. Differentiating themselves in a crowded market, companies are also investing in smart inhalers and digital health solutions to increase patient outcomes and medication adherence.
GlaxoSmithKline plc
AstraZeneca plc
Novartis AG
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd
Sanofi S.A.
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Asthma Treatment Market (2018 – 2022)
3.2. Global Asthma Treatment Market (2023 – 2031)
3.2.1. Market Segment By Drug Class (2023 – 2031)
3.2.2. Market Segment By Route of Administration (2023 – 2031)
3.2.3. Market Segment By Distribution Channel (2023 – 2031)
3.2.4. Market Segment By End-User (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Shift towards biologics and targeted therapies for severe asthma
4.1.2. Increasing adoption of smart inhalers and digital health solutions
4.1.3. Growing focus on combination therapies for improved efficacy
4.2. Market Drivers
4.2.1. Rising prevalence of asthma and increasing environmental pollution
4.2.2. Advancements in drug delivery technologies
4.2.3. Growing healthcare expenditure and improving access to treatments
4.3. Market Restraints
4.3.1. Patent expirations and increasing competition from generic drugs
4.3.2. Stringent regulatory requirements for drug approval
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY DRUG CLASS (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Long-Term Control Medications
5.2. Quick-Relief Medications
5.3. Combination Medications
6. BY ROUTE OF ADMINISTRATION
6.1. Oral
6.2. Inhaled
6.3. Injectable
7. BY DISTRIBUTION CHANNEL
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. BY END-USER
8.1. Hospitals
8.2. Homecare Settings
8.3. Specialty Clinics
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. GlaxoSmithKline plc
12.2. AstraZeneca plc
12.3. Novartis AG
12.4. Boehringer Ingelheim International GmbH
12.5. Merck & Co., Inc.
12.6. Teva Pharmaceutical Industries Ltd.
12.7. F. Hoffmann-La Roche Ltd
12.8. Sanofi S.A.
12.9. Regeneron Pharmaceuticals, Inc.
12.10. Genentech, Inc.
12.11. Mylan N.V.
12.12. Cipla Limited (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
By Drug Class:
Long-Term Control Medications
Quick-Relief Medications
Combination Medications
By Route of Administration:
Oral
Inhaled
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By End-User:
Hospitals
Homecare Settings
Specialty Clinics
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
